tldrdailynews.com logo

"Semaglutide's Heart-Healthy Benefits Boost Novo Nordisk and Eli Lilly's Outlook"

1 min read
Source: Barron's
"Semaglutide's Heart-Healthy Benefits Boost Novo Nordisk and Eli Lilly's Outlook"
Photo: Barron's
TL;DR

Data released by Novo Nordisk confirms that their weight loss drug Wegovy can reduce the risk of strokes and heart attacks, but concerns over the cost of the medicine remain.

Topics:top-newsbiotech-and-pharma#biotech-and-pharma#cost#novo-nordisk#strokes-and-heart-attacks#wegovy#weight-loss-drugs
Share this article
  1. The Outlook for Weight-Loss Drugs Just Got 'Turbocharged.' It's Good for Eli Lilly, Novo Nordisk. - Barrons  Barron's
  2. Weight loss drug may improve heart health, new research finds  NBC News
  3. Novo Nordisk shares rise as Wegovy shows heart benefits beyond weight loss  Yahoo Finance
  4. Wegovy cuts risk of serious heart problems by 20%: landmark study  New York Post
  5. Semaglutide reduces risk of major cardiovascular events by 20%, finds study  The BMJ

Want the full story? Read the original reporting

Read on Barron's